About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

21–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Male and female subjects of non-childbearing potential between the ages of 21 and 70.
Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight \>110 lbs.

You may not be if

Recent (6 months) unstable concurrent disease.
History of allergic disease or drug allergies.
Any condition affecting food consumption or absorption.

The record

StatusTerminated

PhasePhase 1

Taking part4

StartedSep 2013

UpdatedSep 17, 2014

Conditions

Type 2 Diabetes Mellitus (T2DM)

Where2

Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States

Clareo Health | Multiple Dose Study Of PF-05231023 In Obese Adult Subjects